Home
Search

Press Releases

Get the latest on BIO’s announcements, positions, and views.

Featured Press Releases
BIO Statement on Proposed Rule to Implement…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the proposed Outbound Investment Security Program (OISP) rule:"The Administration is correct that…
Learn more
BIO Statement on the FDA’s ‘Fit-for-Purpose Rare…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’“Today’s announcement is an important step…
Learn more
BIO Statement on Finalization of the Globe Model
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the finalization of the GLOBE model.“Biotechnology is one of America's greatest strengths, delivering…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO is Now Accepting Nominations for its Fourth Annual Rosalind Franklin Award
March 8, 2017
BIO began accepting nominations for its fourth annual Rosalind Franklin Award for Leadership in Industrial Biotechnology.  Each year, this award is given to an outstanding woman in the industrial biotechnology sector who has made…
BIO Presents Sen. John Thune (R-S.D.) Legislator of the Year Award
February 28, 2017
The Biotechnology Innovation Organization (BIO) today presented Senator John Thune (R-S.D.) its Industrial & Environmental Section Legislator of the Year Award, recognizing the Senator’s steadfast commitment to growing South Dakota’s and…
BIO Submits Comments on EPA’s Proposed Denial of Petitions for Rulemaking to Change the RFS Point of Obligation
February 22, 2017
In BIO’s view, granting the petitions to change the point of obligation would create unnecessary regulatory uncertainty and fail to further the statutory goals of the Renewable Fuel Standard (“RFS”) program.
Nominations Now Open for the BIO George Washington Carver Award for Innovation in Industrial Biotechnology
February 22, 2017
The ninth annual George Washington Carver Award will recognize an individual who has made a significant contribution to building the biobased economy by applying industrial biotechnology to create sustainable and environmentally…
BIO Submits Comments on EPA Renewables Enhancement and Growth Support Rule
February 16, 2017
The Biotechnology Innovation Organization (BIO) today submitted comments on the Environmental Protection Agency’s recently proposed Renewables Enhancement and Growth Support (REGS) Rule. BIO supports EPA’s ongoing efforts to improve the efficiency…
BIO Statement on National Academies’ Consensus Study on Human Gene Editing
February 14, 2017
Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement  regarding the Consensus Study on Human Gene Editing, released today by the Human Gene Editing Initiative of the National Academies…
EU’s Anti-Science Comitology Reform Threatens Innovation
February 14, 2017
Washington, D.C. (February 14, 2017) – The European Commission announced today a proposal to revise its Comitology Regulation forcing policy decisions to individual EU member countries.
BIO Announces Gary Andres as the New Senior Executive Vice President of Public Affairs
February 14, 2017
Long-time Majority Staff Director of the House Energy and Commerce Committee Dr. Gary Andres joins BIO as Senior Executive Vice President of Public Affairs.
Registration Now Open for the 14th Annual BIO World Congress on Industrial Biotechnology
February 8, 2017
BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology.  The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal,…
BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation
January 31, 2017
Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation: